Core Viewpoint - Zhonghui Biotech-B (02627.HK) announced that its quadrivalent influenza virus subunit vaccine has been included in the preliminary review list of the national commercial health insurance innovative drug catalog, marking it as the only vaccine product in this year's list [1] Group 1: Product Approval and Features - The quadrivalent influenza virus subunit vaccine, marketed as Huiru Kangsxin, received new drug application (NDA) approval from the National Medical Products Administration of China in May 2023 [1] - This vaccine is approved for individuals aged three and above, with a specification of 15μg/0.5ml for the hemagglutinin concentration of the virus strains [1] - It is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025, targeting two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages) [1] Group 2: Advantages of the Vaccine - The product represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of component antigens, and a lower risk of adverse reactions [1]
中慧生物-B(02627.HK)：四价流感疫苗"慧尔康欣"入选国家商保创新药品目录 为首款入围疫苗产品